Effect of resumption of second line drugs in patients with rheumatoid arthritis that flared up after treatment discontinuation

Annals of the Rheumatic Diseases

Volumn 56, Issue 4, 1997, Pages 235-239

  Ten Wolde, Saskia ^a   Hermans, Jo ^a   Breedveld, Ferdinand C ^a   Dijkmans, Ben A C ^b  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; AZATHIOPRINE; GOLD; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PENICILLAMINE; SALAZOSULFAPYRIDINE;

ADULT; AGED; ANEMIA; ARTICLE; DERMATITIS; DISEASE SEVERITY; DRUG EFFECT; DRUG SAFETY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 0030963885     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.56.4.235     Document Type: Article

References (17)

1. de Silva M, Hazleman BL. ong-term azathioprine in rheumatoid arthritis: a double-blind study. Ann Rheum Dis 1981;40:560-3.
2. Cade R, Stein G, Pickering M, Schlein E, Spooner G. Low dose, long-term Treatment of rheumatoid arthritis with azathioprine. South Med J 1976;69:388-92.
3. Ahern MJ, Hall ND, Case K, Maddison PJ. D-penicillamine withdrawal in rheumatoid arthritis. Ann Rheum Dis 1984; 43:213-7.
4. Kremer JM, Rynes RI, Bartholomew LE. Severe flare of rheumatoid arthritis after discontinuation of long-term methotrexate therapy. Am J Med 1987;82:781-6.
5. Szanto E. Low-dose methotrexate in rheumatoid arthritis: effect and tolerance. Scand J Rheumatol 1986;15:97-102.
6. Kean WF, Anastassiades TP. Long term chrysotherapy: incidence of toxicity and efficacy during sequential time periods. Arthritis Rheum 1979;22:495-501.
7. Sagransky DM, Greenwald RA. Efficacy and toxicity of retreatment with gold salts: a retrospective review of 25 cases. J Rheumatol 1980;7:474-8.
8. Bagnall AW. The value of chloroquine in rheumatoid disease: a four-year study of continuous therapy. Can Med Assoc J 1957;77:182-94.
9. Jones E, Jones JV, Woodbury JF. Response to sulfasalazine in rheumatoid arthritis: life table analysis of a 5-year followup. J Rheumatol 1991;18:195-8.
10. Hoh KF, Dwosh IL, Ford PM, Anastassiades TP, Kelly HG. Drug-related disease remissions in rheumatoid arthritis. Arthritis Rheum 1981;24(suppl 72):86.
11. Evers AE, Sundstrom WR. Second course gold therapy in the treatment of rheumatoid arthritis. Arthritis Rheum 1983;26:1071-5.
12. Klinkhoff AV, Teufel A. The second course of gold. J Rheumatol 1995;22:1655-66.
13. ten Wolde S, Breedveld FC, Hermans J, Vandenbroucke JP, van de Laar MAFJ, Markusse HM, et al. Randomised placebo-controlled study of stopping second-line drugs in rheumatoid arthritis. Lancet 1996;347:347-52.
14. Arnett FC, Edworthy SM, Block DA. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31:315-24.
15. Pinals RS, Masi AT, Larsen RA. Preliminary criteria for clinical remission in rheumatoid arthritis. Arthritis Rheum 1981;24:1308-15.
16. Ritchie DM, Boyle JA, Mclnnes JM, Jasani MK, Dalakos TG, Grieveson P, et al. Clinical studies with an articular index for the assessment of joint tenderness in patients with rheumatoid arthritis. Q J Med 1968;37:393-406.
17. Paulus HE, Egger MJ, Ward JR, Williams HJ. Analysis of improvement in individual rheumatoid arthritis patients treated with disease-modifying antirheumatic drugs, based on the findings in patients treated with placebo. The Cooperative Systematic Studies of Rheumatic Diseases Group. Arthritis Rheum 1990;33:477-84.